36IN - New treatment approaches in hereditary cancer: The route towards personalized care
|Date||29 September 2012|
|Event||ESMO Congress 2012|
|Session||How can medical oncologists deal with the new wave of genetic information about their patients?|
|Topics|| Familial Cancer
Patients diagnosed with tumors arising on the basis of hereditary cancer syndromes represent a relatively small fraction from the total of cancer cases. However, the risks to develop different types of tumors among carriers highlight the need to develop surveillance strategies and preventive interventions to decrease the burden of cancer in this population. The specific molecular characteristics displayed by these tumors make them ideal candidates to identify new targets and implement not only personalized cancer treatments but also targeted chemoprevention strategies. In addition, hereditary tumors have served as a model to gain further knowledge in the molecular biology of cancer and to develop targeted drugs. The best example in this context is the case of PARP inhibitors and breast and ovarian tumors arising in families diagnosed with Hereditary Breast and Ovarian Cancer Syndrome (BRCA 1 and 2 mutations). In this presentation we will review the most recent research advances on target identification and drug development for hereditary cancer syndromes with a special emphasis in hereditary gastrointestinal cancers.Disclosure
The author has declared no conflicts of interest.